FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer

…, T Palmby, SJ Schrieber, Q Liu, J Wang… - Clinical cancer …, 2014 - AACR
On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla; Genentech,
Inc.) for use as a single agent for the treatment of patients with human epidermal growth …

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer

…, HN Horne, J Liu, C Liu, SJ Schrieber, J Yu… - Clinical Cancer …, 2017 - AACR
On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA;
Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline …

Dotmark–a benchmark for discrete optimal transport

J Schrieber, D Schuhmacher, C Gottschlich - IEEE Access, 2016 - ieeexplore.ieee.org
… we always have m = n = r2, and (xi)1≤i≤m = (yj)1≤j≤n form a regular square grid of
resolution r × r in R2, but since it is more intuitive, we keep different notation for source locations …

Optimal transport: Fast probabilistic approximation with exact solvers

M Sommerfeld, J Schrieber, Y Zemel, A Munk - Journal of Machine …, 2019 - jmlr.org
We propose a simple subsampling scheme for fast randomized approximate computation of
optimal transport distances on finite spaces. This scheme operates on a random subset of …

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C

RL Hawke, SJ Schrieber, TA Soule… - The Journal of …, 2010 - Wiley Online Library
Silymarin, derived from the milk thistle plant Silybum marianum, is widely used for self‐treatment
of liver diseases, including hepatitis C virus (HCV), and its antiviral activity has been …

[HTML][HTML] Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis

TM Herndon, C Ausin, NN Brahme, SJ Schrieber… - Plos one, 2023 - journals.plos.org
Biosimilars are increasingly available for the treatment of many serious disorders, however
some concerns persist about switching a patient to a biosimilar whose condition is stable …

Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract

Z Wen, TE Dumas, SJ Schrieber, RL Hawke… - Drug Metabolism and …, 2008 - ASPET
Silymarin, a mixture of polyphenolic flavonoids extracted from milk thistle (Silybum marianum),
is composed mainly of silychristin, silydianin, silybin A, silybin B (SB B ), isosilybin A (ISB …

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity

SJ Schrieber, Z Wen, M Vourvahis, PC Smith… - Drug Metabolism and …, 2008 - ASPET
Silymarin, used by 30 to 40% of liver disease patients, is composed of six major flavonolignans,
each of which may contribute to silymarin's hepatoprotective properties. Previous studies …

Methodology to gather multimodal urban trip generation data

…, J Henson, R Weinberger, J Schrieber… - Transportation …, 2015 - journals.sagepub.com
Assessments of the impact of new land use development on the transportation network often
rely on the ITE Trip Generation Manual informational report. Current ITE rates generally …

[HTML][HTML] Advancing biosimilar development using pharmacodynamic biomarkers in clinical pharmacology studies

J Li, J Florian, E Campbell, SJ Schrieber… - Clinical …, 2020 - ncbi.nlm.nih.gov
To ensure US patients realize the public health benefit of a robust, competitive market for
biosimilar products, the US Food and Drug Administration (FDA) is focused on improving the …